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Summary 
Introduction 
Health Problem 
Gastroesophageal reflux disease (GERD) is defined according to the Montreal 
consensus as a condition that develops when the reflux of stomach contents 
causes troublesome symptoms and/or complications, whereby troublesome 
means that they adversely affect an individual’s well-being [1]. 
From a surgical perspective, GERD is the failure of the antireflux barrier, 
caused by a defective LES, a gastric emptying disorder, or failed esophageal 
peristalsis. The abnormalities result in a spectrum of disease ranging from 
symptoms only, such as heartburn, to esophageal tissue damage with or with-
out subsequent complications including malignancy or airway disease [1]. 
Description of Technology 
Electric stimulation therapy (EST) represents a novel method for the surgi-
cal treatment of GERD. The EST comprises of three components: a bipolar 
stimulation lead with two stitch electrodes, an implantable pulse generator, 
and an external programmer [2]. The EST implant procedure is performed 
using standard laparoscopic techniques where a pair of electrodes is placed 
in the anterior part of the lower esophagus and sutured in place [3]. The wires 
are then connected to a stimulator placed in the subcutaneous pocket in left 
upper quadrant of the abdominal wall [3]. The goal of the intervention is to 
reinforce the weak lower esophageal sphincter (LES) by delivering mild elec-
trical signals to the LES throughout the day. The stimulation aims to restore 
normal function of the LES, preventing reflux from the stomach entering the 
esophagus. 
 
Methods 
The EUnetHTA Core Model for Rapid Relative Effectiveness was the main 
source for selecting relevant assessment elements. We conducted a systemat-
ic literature search (without restriction on publication date) in bibliographic 
databases (Medline via Ovid, Embase, the Cochrane Library, PubMed, data-
base of the Centre for Reviews and Dissemination) to anwer the research ques-
tions in the domains effectiveness and safety. Two researcher selected the rel-
evant documents (in English) independently. The Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) methodology was 
used for qualitatively summarising the results for the domain: „Safety”. 
Domain effectiveness 
For analysing clinical effectiveness, prospective controlled studies were in-
cluded. The crucial outcome to derive a recommendation was GERD HRQL 
score. 
Domain safety 
For analysing safety, prospective controlled and uncontrolled studies were in-
cluded. The crucial outcomes to derive a recommendation were: device ero-
sion and trocar perforation of the small bowel during laparoscopy. Other rel-
evant outcomes were post-operative bloating/belching, post-operative dyspha-
gia, pain/discomfort, and nausea/vomiting. 
Gastroesophageal  
reflux disease 
failure of the antireflux 
barrier, the lower 
esophageal sphincter 
(LES) 
EST, a novel surgical 
treatment option for 
GERD 
 
laparoscopic intervetion 
 
electrical stimulation to 
reinforce the weak LES 
based on EUnetHTA 
Core Model, systematic 
literature search in  
5 databases, GRADE 
inclusion criteria  
for effectiveness 
inclusion criteria  
for safety 
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Results 
Available evidence 
A total of two single-arm prospective case series and one prospective registry 
were eligible for inclusion in the current report. Overall, safety was evaluated 
in the total of 70 patients.  
Clinical effectiveness 
No study fulfilled the study inclusion criteria for assessing clinical  
effectiveness of the EST. 
Safety 
In the absence of data from controlled studies, no comparisons can made be-
tween the EST and the surgical alternative treatment, laparoscopic fundopli-
cation (LF). Device and procedure related complications were reported in one 
study with 6 months follow-up [4]. Lead erosion through esophagus occurred 
in 2.4% out of 42 patients and was followed by the device explantation. One 
procedure related complication, trocar perforation of the small bowel during 
laparoscopy, occurred also in 2.4% out of 42 patients. No other device or 
procedure related complications were reported.  
A number of short-term post-operative harms occurred. The following adverse 
events occurred in one study [4] (in % of patients): constipation 2.4%, epigas-
tric pain 2.4%, hiccups 4.8%, inability to vomit 4.8%, and fever 2.4%. The fol-
lowing adverse events occurred in both case series [4, 5] (in % of patients): 
post-operative bloating/belching in 7.1% and 0%, post-operative dysphagia 
in 9.5% and 0%, nausea/vomiting in 7.1% and 12%, and pain/discomfort in 
45.2% and 20%. No new adverse events occurred in the registry study. 
Upcoming evidence 
There is an ongoing study in the US and Europe that is a multicenter,  
randomized, double-blind, sham-controlled clinical trial (NCT02749071). 
Reimbursement 
Currently, the use of EST for the treatment of GERD is not reimbursed by 
the Austrian health care system. 
 
Discussion 
Overall, the quality of evidence was very low and the overall risk of bias was 
considered moderate. Internal validity of the trials conducted was undermined 
by the use of the concomitant therapy of Proton Pump Inhibitors (PPIs) in all 
trials.  
Major advantages of the EST known to date are that it is less invasive and 
reversible, its implantation is associated with a short learning curve for the 
surgeon, it presumably allows a faster return to normal diet, and it requires 
a shorter hospital stay compared to LF. 
The target population of the EST, however, seems to be less severe patients 
not indicated for LF and hence, a sham RCT is needed to confirm efficacy of 
the EST. Crucial outcome measures should include the device’s ability to re-
duce the likelihood of developing GERD complications, like esophageal can-
cer, and the long-term safety considerations, like the durability of the device 
and device removals. 
2 single arm  
prospective case series,  
70 patients 
no study fulfilled the 
study inclusion criteria  
no direct comparison  
for EST and standard 
practice 
 
lead erosion in  
2.4% patients  
(out of 42 patients)  
postoperative AEs: 
constipation, pain, 
hiccups, inability to 
vomit, fever, post 
operative bloating  
and dysphagia 
1 ongoing multicentre 
RCT 
currently  
not reimbursed 
quality evidence needed, 
high risk of bias 
 
advantages of the EST 
are lesser invasiveness, 
easier intervention, 
shorter hospital stay 
 
target population are 
GERD patients not 
indicated for LF 
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Conclusion 
The current evidence is not sufficient to prove that the EST is at least equally 
effective and as safe as the comparator LF. There are no available compara-
tive data on the two procedures or placebo controlled data on the EST and 
hence, no conclusions are made about the device effectiveness. Concerning 
safety, only device related complications were reported based upon data from 
prospective case series. These suggest a relatively safe profile of the EST that, 
however, needs to be confirmed by a high quality RCT, which will potential-
ly influence the effect estimate considerably. Re-evaluation is recommended 
in 2022, as December 2021 is the estimated ongoing study (NCT02749071) 
completion date. 
The inclusion in the catalogue of benefits is currently not recommended. 
 
 
  
current evidence does 
not prove effectiveness 
of the EST and safety 
needs to be confirmed 
 
 
 
reevaluation in 2022 
inclusion not 
recommended 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Die gastroösophageale Refluxkrankheit (GERD) ist eine häufige Erkrankung 
in den Industrieländern der westlichen Welt mit einer Prävalenz von bis zu 
15 % und einer zunehmenden Inzidenz. Aufgrund ihrer zunehmenden Häu-
figkeit beansprucht die Behandlung von GERD wachsende Ressourcen. Zu 
den beeinflussenden Faktoren für die Entstehung von GERD zählen falsche 
Ernährung (Fettleibigkeit, erhöhter Fettkonsum, Essen unmittelbar vor dem 
zu Bett gehen) und ein passiver Lebensstil (Bewegungsmangel). 
Typische Symptome von GERD sind: Sodbrennen, Aufstoßen, Magenschmer-
zen. Zu den atypischen Symptomen zählen: chronischer Husten, Heiserkeit, 
Dysphagie, Schmerzen in der Brust, chronische Aspiration, Bronchitis, Sinu-
sitis. Auf Basis der Häufigkeit und Schwere der Reflux-Symptome, wird von 
milder, moderater und schwerer GERD gesprochen, jedoch ohne explizite 
Definition über die Dauer der Erkrankung und die Art der Messung der ver-
schiedenen Stadien. 
Der natürliche Verlauf der Erkrankung ist unklar. Traditionell wird die Krank-
heit als Spektrum beginnend mit nicht-erosivem Reflux (NERD), der sich 
zu GERD (erosive Ösophagitis, Stenose, Barrett-Ösophagus) entwickelt, be-
schrieben. Das Management von GERD wird durch die Schwere der Symp-
tome bestimmt. Die Leitlinien der „American College of Gastroenterology“ 
(ACG) und der „Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen 
Fachgesellschaften“ (AWMF) schlagen ein schrittweises Vorgehen vor  
 Als erste Interventionen werden Veränderungen in der Ernährung 
und im Lebensstil vorgeschlagen, 
 Gewichtsverlust für GERD-PatientInnen, die übergewichtig sind, 
 Oberkörperhochlage und Vermeidung von Mahlzeiten 2-3 Stunden 
vor dem Zubettgehen für PatientInnen mit nächtlicher GERD,  
 bei mild bis moderater Schwere der Symptome:  
ein H2-Rezeptor-Antagonist (H2RA) Therapie, 
 wenn eine H2RA Therapie nicht ausreichend ist, und der/die PatientIn 
moderate bis schwere Symptome hat: Initiierung einer 8-wöchigen 
Therapie mit Protonenpumpeninhibitoren (PPI),  
 bei anhaltenden GERD Symptomen ist eine PPI-Erhaltungstherapie 
(mit niedriger Dosierung) indiziert. 
 Eine Operationsindikation ist gegeben, wenn zusätzlich zur langfris-
tigen Behandlungsbedürftigkeit folgende Indikationskriterien erfüllt 
sind: intolerable Reflux-induzierte Restbeschwerden oder eine Unver-
träglichkeit gegenüber der PPI-Therapie besteht. 
 
gastroösophageale 
Refluxkrankheit 
(GERD): 
Prävalenz 15 %  
 
Ernährung & Lebensstil 
Symptome:  
Sodbrennen, Aufstoßen, 
Magenschmerzen 
Schweregrade: mild, 
moderat, schwer 
progrediente 
Erkrankung 
 
ACG & AWMF: 
schrittweises Vorgehen 
bei Interventionen 
Gewichtsverlust, 
Vermeidung von 
Mahlzeiten vor 
Zubettgehen,  
H2RA Therapie, 
8 Wochen PPI, 
PPI Erhaltungstherapie, 
Operation:  
Therapie 2. Wahl 
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Beschreibung der Technologie 
Die elektrische Stimulationstherapie (EST) stellt eine neuartige Methode zur 
chirurgischen Behandlung von GERD dar. Die EST besteht aus drei Kom-
ponenten: einer bipolaren Stimulationsleitung mit zwei Maschenelektroden, 
einem implantierbaren Impulsgenerator und einem externen Programmierer 
[2]. Die EST-Implantat-Prozedur wird unter Verwendung von Standard-lapa-
roskopischen Techniken durchgeführt, bei denen ein Paar Elektroden in den 
vorderen Teil des unteren Ösophagus platziert und an der Stelle vernäht wird 
[3]. Die Drähte werden dann mit einem Stimulator verbunden, der in der sub-
kutanen Tasche im linken oberen Quadranten der Bauchwand platziert ist [3]. 
Das Ziel der Intervention ist es, den schwachen unteren Ösophagussphink-
ter (LES) durch die Bereitstellung von milden elektrischen Signalen an die 
LES den ganzen Tag zu verstärken. Die Stimulation zielt darauf ab, die nor-
male Funktion der LES, die Vermeidung von Reflux aus dem Magen in die 
Speiseröhre, wiederherzustellen. 
 
Methoden 
Die Beantwortung der Forschungsfragen bezüglich Wirksamkeit und Sicher-
heit erfolgte anhand einer systematischen Literatursuche in folgenden Daten-
banken: 
 Medline via Ovid, 
 Embase, 
 the Cochrane Library, 
 CRD (DARE, NHS-EED, HTA) 
Zusätzlich wurde eine Handsuche durchgeführt und der Hersteller kontak-
tiert. Die Studienauswahl erfolgte unabhängig durch beide AutorInnen (MS, 
KH). Der Erstautor (MS) extrahierte die Studiendaten und die Zweitautorin 
(KH) kontrollierte die Daten. 
Die Daten der für die Entscheidung herangezogenen Endpunkte wurden aus 
den einzelnen Studien zusammengefasst und nach GRADE (Grading of Re-
commendations Assessment, Development and Evaluation) bewertet. Zusätz-
lich wurde das Bias-Risiko der Studien von beiden AutorInnen unabhängig 
voneinander bewertet. 
Klinische Wirksamkeit 
Zur Bewertung der Wirksamkeit des LINX® Reflux Management Systems 
wurde der GERD HRQL score als entscheidend für eine Empfehlung erach-
tet. Weitere wichtige Endpunkte waren Sodbrennen, tägliches Aufstoßen, ex-
tra-ösophageale Symptome, Absetzen oder Reduktion von PPI-Medikamen-
ten. 
Der GERD HRQL score misst die Veränderungen in typischen GERD-Symp-
tomen nach einer chirurgischen oder medizinischen Behandlung. Der GERD 
HRQL score enthält Fragen zu Sodbrennen, Schwierigkeiten beim Schlucken, 
Blähungen und zur Medikamenteneinnahme. Die bestmögliche Punktzahl ist 
0 (asymptomatisch), die schlechteste Punktzahl ist 50.  
EST neue Technologie 
für chirurgische GERD 
Therapie 
 
laparaskopischer 
Eingriff 
 
elektrische Stimulation 
um normale LES 
Funktion herzustellen 
Suche nach 
Publikationen in 
mehreren Datenbanken 
Kontakt mit Hersteller 
4-Augenprinzip  
bei Studienauswahl, 
Extraktion der Daten, 
Kontrolle 
GRADE &  
Risk of Bias Beurteilung 
entscheidender 
Endpunkt zur 
Beurteilung der 
Wirksamkeit:  
GERD HRQL 
GERD HRQL score  
misst GERD-Symptome: 
 
0-50 Punkte  
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Sicherheit 
Zur Bewertung der Sicherheit wurden die folgenden  
entscheidenden Endpunkte für eine Empfehlung herangezogen:  
 Erosion des Produktes 
 Trokarperformation im Zuge des laparaskopischen Eingriffes 
Weitere wichtige Endpunkte waren:  
 Post-operative übermäßige Blähungen und Aufstoßen 
 Übelkeit und Erbrechen 
 Schmerzen, Unwohlsein 
 
Ergebnisse 
Verfügbare Evidenz 
Insgesamt konnten zwei einarmige prospektive Fallserien und ein Fallregis-
ter identifiziert werden. Da keine der Studien die Einschlusskriterien für die 
Bewertung der Wirksamkeit erfüllte, konnten die Studien mit einer Gesamt-
zahl von 70 PatientInnen nur zur Bewertung der Sicherheit herangezogen 
werden. 
Klinische Wirksamkeit 
Keine Studie erfüllte die Einschlusskriterien zur Beurteilung der klinischen 
Wirksamkeit. 
Sicherheit 
Aufgrund fehlender kontrollierter Studien konnten keine Vergleiche zwischen 
EST und der derzeitigen Standardtherapie laparoskopische Fundoplikatio 
(LF) durchgeführt werden. Produkt- und prozessbedingte Komplikationen 
wurden in einer Studie mit einem Follow-up von 6 Monaten berichtet. Ero-
sionen im Bereich der Speiseröhre traten in 2,4 % der 42 PatientInnen auf, 
woraufhin die Geräte explantiert wurden. Eine Trokarperforation der Dünn-
darmwand im Zuge der Laparoskopie trat in 2,4 % der 42 PatientInnen ein. 
Es wurden keine weiteren prozess- oder produktbezogenen Komplikationen 
beschrieben.  
Des Weiteren wurde eine Reihe kurzfristiger postoperativer Schäden berich-
tet (Anzahl der PatientInnen in Prozent der jeweiligen Studie): Verstopfung 
2,4 %, epigastrische Schmerzen 2,4 %, Schluckauf 4,8 %, Erbrechen und Fie-
ber 2,4 %, postoperative Blähungen/Aufstoßen in 7,1 % und 0 %, postoperati-
ve Dysphagie in 9,5 % und 0 %, Übelkeit/Erbrechen in 7,1 % und 12 % und 
Schmerzen/Unwohlsein in 45,2 % und 20 %. Die Patientenregisterstudie be-
richtete keine zusätzlichen unerwünschten Ereignisse. 
Laufende Studien 
Derzeit gibt es eine laufende randomisierte, multizentrische doppel-blinde 
Studie in den USA und Europa, die die Intervention im Vergleich zu einer 
Scheinbehandlung untersucht (NCT02749071). 
Kostenerstattung 
EST wird in Österreich zurzeit nicht erstattet. 
 
entscheidende 
Endpunkte zur 
Beurteilung der 
Sicherheitt:  
Prozedur- und  
Produkt-induzierte 
Komplikationen 
2 prospektive,  
einarmige Fallserien,  
1 Fallregister 
70 Patienten 
keine Studien zur 
Beurteilung der 
Wirksamkeit 
Erosion und 
Trokarperforation in 
2.4 % der PatientInnen 
Postoperative AE: 
Blutungen, Verstopfung, 
Oberbauchschmerzen, 
Schluckauf, gestörter 
Würgereflex, Fieber 
1 laufendes RCT 
derzeit nicht erstattet 
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Diskussion 
Insgesamt war die Qualität der Evidenz, aufgrund der Fehlenden Daten aus 
kontrollierten Studien, der Heterogenität der Ergebnisse, und der kleinen 
Stichprobengröße, sehr gering. Das Gesamtrisiko für Verzerrungen wurde als 
moderat eingestuft. Die hochspezifische PatientInnengruppe der Studien ist 
nicht repräsentativ für GERD-PatientInnen, die eine chirurgische Therapie 
benötigen. 
Die wesentlichen Vorteile der EST wären die Reversibilität und die niedri-
gere Invasivität des Verfahrens, die vermutlich eine schnellere Rückkehr zur 
normalen Diät erlaubt. Die Implantation des Produktes ist mit einer kurzen 
Lernkurve für ChirurgInnen assoziiert. Des Weiteren weist die Intervention 
einen kürzeren Krankenhausaufenthalt im Vergleich zur LF auf. 
Im Unterschied zur LF, die nur bei schweren GERD Fällen indiziert ist, 
scheint allerdings die Zielpopulation für EST auch moderatere GERD Pati-
entInnen einzubeziehen, für die LF und chirurgische Verfahren primär nicht 
indiziert wären. Daher ist zur Beurteilung der Wirksamkeit ein Schein-RCT 
essentiell, in der das Gerät implantiert, bei der Kontrollgruppe aber vorerst 
nicht aktiviert wird.  
Entscheidende Endpunkte für zukünftige Studien und die Bewertung der 
Wirksamkeit und Sicherheit sollten zusätzlich Langzeitfolgen beinhalten – 
wie zum Bespiel die Verminderung der Zahl an Speiseröhrenkrebserkran-
kungen und die Haltbarkeit des Produktes. 
 
Empfehlung  
Die vorhandene Evidenz lässt keine Rückschlüsse zu, ob EST mindestens 
gleich wirksam und genauso sicher ist wie der Komparator LF.  
Es gibt keine kontrollierten Studien, um die Wirksamkeit von EST im Ver-
gleich zu LF oder einer Scheinbehandlung zu bewerten. Des Weiteren konn-
ten entscheidende Sicherheitsendpunkte nur auf Basis von Daten aus pros-
pektiven Fallserien bewertet werden. Diese deuten darauf hin, dass EST ein 
relativ sicheres Verfahren ist. Jedoch ist eine Bestätigung dieser Ergebnisse 
durch ein RCT notwendig, da dies die Empfehlung stark beeinflussen könnte.  
Eine neuerliche Evaluierung wird für 2022 empfohlen, da im Dezember 2021 
das laufende Schein-RCT fertig gestellt werden wird (NCT02749071). 
Auf Basis der derzeit verfügbaren Evidenz wird die Aufnahme von EST in 
den Leistungskatalog nicht empfohlen. 
 
Qualität der Evidenz 
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Evidenz nicht 
ausreichend um 
Wirksamkeit und 
Sicherheit zu bewerten 
Re-Evaluierung 2022 
Aufnahme nicht 
empfohlen 
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1 Scope 
1.1 PICO question 
Is Electric Stimulation Therapy (EST) in comparison to the standard surgi-
cal treatments (Nissen fundoplication, partial or Toupet fundoplication) in 
patients with chronic gastroesophageal reflux disease (GERD) more effective 
or equally effective concerning improvement in GERD-Health-related quali-
ty of life (HRQL), and safer regarding the post-operative side effects and se-
rious adverse events? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Adult patients with chronic (>6 months) GERD, diagnosis based on 24 pH monitoring, 
LES end-expiratory pressure of 5-15 mmHg, peristaltic contractions seen in ≥50% of 
swallows with a contraction amplitude of ≥30 mmHg during baseline esophageal 
manometry, typical symptoms of GERD (heartburn, or regurgitation), esophagitis 
grade C or lower (LA classification), and at least partial response to therapeutic 
medication with PPIs as 2nd line treatment. 
MeSH-term: Electric Stimulation Therapy, Electric Stimulation 
Intervention Electric stimulation therapy device (EST) inserted through laparoscopic surgery 
Product name: EndoStim® LES Stimulator 
MeSH-term: Gastroesophageal reflux, Gastrooesophageal reflux 
Control  Sham treatment (placebo)  
 Standard surgical treatment of GERD: Nissen fundoplication, partial or Toupet 
fundoplication 
 PPI therapy 
Outcomes  
Efficacy Clinical endpoint: 
 GERD-Health-related quality of life (HRQoL) 
Intermediate outcomes: 
 Heartburn 
 Regurgitation 
 Extra-esophageal symptoms 
 Discontinuation of anti-reflux medication (PPIs) 
 Improvement in LES pressure 
Safety Adverse events (AEs), serious adverse events (SAEs): 
 Dysphagia 
 Excessive bloating 
 Inability to belch or vomit 
 Operation related complications 
 Device related complications (migration, erosion, malfunction, removal, removal) 
 Re-hospitalisation 
 Re-operation 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD) 
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Study design  
Efficacy Randomised controlled trials (RCTs) 
Prospective non-randomised controlled trials (CTs) 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective single-arm studies, registries 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is electric stimulation therapy (EST) and the alternative standard treatment option(s)? 
B0002 What is the claimed benefit of the EST in relation to the alternative standard treatment option? 
B0003 What is the phase of development and implementation of the EST and the alternative  
standard treatment option? 
B0004 Who administers the EST and fundoplication and in what context and level of care  
are they provided? 
B0008 What kind of special premises are needed to use the EST and the alternative standard 
treatment options? 
B0009 What supplies are needed to use the EST and the alternative standard treatment option? 
A0020 For which indications has the electric stimulation therapy device (ESTD) received marketing 
authorisation or CE marking? 
A0021 What is the reimbursement status of the EST? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions and for what purposes is the EST used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for gastrooesophageal reflux disease (GERD)? 
A0004 What is the natural course of GERD? 
A0005 What is the burden of GERD for the patients with the disease or health condition? 
A0006 What are the consequences of GERD for the society? 
A0024 How is GERD currently diagnosed according to published guidelines and in practice? 
A0025 How is GERD currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 What is the expected annual utilisation of the EST? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of the EST on mortality?  
D0005 How does the EST affect heartburn, regurgitation, and extraesophageal symptoms? 
D0006 How does the EST affect the continuation with PPI therapy? 
D0011 What is the effect of the EST on dysphagia and bloating? 
D0016 How does the EST affect activities of daily living? 
D0013 What is the effect of the EST on disease-specific quality of life? 
D0017 Were patients satisfied with the EST? 
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Safety 
Element ID Research question 
C0008 How safe is the EST in comparison to LF? 
C0002 Are there harms related to dosage or frequency of applying the technology? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of the technology? 
C0007 Are EST and LF associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of EST and LF? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the POP, MDS, Syngerus, Ohtanen and CRD databases 
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
Health problem and Current Use 
 Handsearch in the POP, MDS, Syngerus, Ohtanen and CRD databases 
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Erdös J, Stanak M. Magnetic Sphincter Augmentation Device (MSAD) 
in patients with gastroesophageal reflux disease (GERD). Decision 
Support Document No. 101; 2016. Vienna: Ludwig Boltzmann Insti-
tute for Health Technology Assessment. 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted from January 2nd to  
February 3rd in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
 PubMed 
At the time of the systematic literature search, no limitations to the study 
design were applied. In addition, handsearch of literature (web-search) was 
performed. After deduplication, overall 345 citations were included. The spe-
cific search strategy employed can be found in the Appendix.  
Quellen 
systematische 
Literatursuche in  
5 Datenbanken  
Methods 
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EndoStim Inc., the manufacturer of EndoStim® LES Stimulator, submitted 
28 publications of which 0 new citations were identified.  
By hand-search, an additional 22 citations were found, resulting in overall 
367 hits. 
 
 
2.4 Flow chart of study selection 
Overall, 367 hits were identified. The references were screened by two inde-
pendent researchers (MS, KH) and in case of disagreement, a third research-
er was involved to solve the differences. The selection process is displayed in 
Figure 2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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(n=65) 
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(n=62) 
 Abstracts (n=39) 
 Background (n=10) 
 Editorials and highlights (n=4) 
 Other study design (n=2) 
 Other intervention (n=1) 
 Interim results (n=3) 
 Not in English (n=3) 
Studies included in 
qualitative synthesis 
(n=3) 
 Case-series (n=2) 
 Registries (n=1) 
Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD) 
18 LBI-HTA | 2017 
2.5 Analysis 
The data retrieved from the selected studies were systematically extracted in-
to a data-extraction-table (see Appendix Table A-1). No further data process-
ing (e.g. indirect comparison) was applied. Two independent researchers (MS, 
KH) systematically assessed the quality of evidence (see Table 7-1) and the 
risk of bias using the checklists presented in the Appendix Table A-2). 
 
 
2.6 Synthesis 
Based on the data-extraction-table (see Appendix Table A-1), data on each se-
lected outcome category were synthesised across studies according to GRADE 
(Grading of Recommendations Assessment, Development and Evaluation) [6]. 
The research questions were answered in plain text format with reference to 
GRADE evidence tables (see Table 7-1). 
 
Systematische 
Datenextraktion 
Zusammenfassung der 
Ergebnisse mit GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is electric stimulation therapy (EST) and the alternative 
standard treatment option? 
The EST comprises of three components: a bipolar stimulation lead with two 
stitch electrodes, an implantable pulse generator (IPG), and an external pro-
grammer (see Figure 3-1) [2]. The stimulation lead is 45 cm long and has ster-
ile bipolar, stitch platinum-iridium electrodes at the end. The IPG is made of 
hermetically sealed titanium case construction (size 65x48x12 mm and weight 
49 g), it is connected to the stimulation leads, and permanently implanted in 
a subcutaneous pocket in the left upper quadrant of the abdomen [2]. The 
IPG contains a medical grade lithium battery, microelectronics, communica-
tion coils, and an accelerometer for sensing patient posture [2]. The IPG is 
programmed by an external programmer via laptop PC software [2]. 
The EST implant procedure is performed using standard laparoscopic tech-
niques. A pair of electrodes are placed in the anterior part of the lower eso-
phagus 1 cm apart and sutured in place [3]. Endoscopic visualization of the 
gastroesophageal junction is used to ensure that the wires do not enter the 
lumen [7]. The wires are then connected to a stimulator placed in the subcu-
taneous pocket in left upper quadrant of the abdominal wall [3]. It is recom-
mended that the patient wears an elastic compression bandage over the pulse 
generator implantation site for 10-14 days in order to reduce the chances of 
seroma formation [8]. 
The stimulator may be switched on or off remotely, and the polarity of its cur-
rent and pattern of stimulation can be modulated. Patients are not supposed 
to be aware of the stimulators activity [3]. The electrical stimulation is initi-
ated 12 hours after the implant procedure. The current is applied intermit-
tently through the day in specified time periods and can be personalized. Elec-
trical stimulation is delivered using a 215-ls pulse at 20 Hz and 3-8 mA in 
30 min sessions, 6-12 time per day [5, 8]. 
 
Figure 3-1: The EST device parts and the EST electrode position and IPG implant location [5, 7] 
EST besteht aus  
3 Komponenten: 
Stimulationsdraht  
mit 2 Elektroden, 
implantierbarer 
Pulsgenerator,  
externer Programmierer 
Implantation erfolgt 
mittels Standard 
laparaskopischem 
Eingriff 
Durch die externe 
Programmierung kann 
der Stimulator an und 
ab geschalten werden, 
sowie die Polarität und 
Stromstärke adaptiert 
werden 
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Marketed products 
There is currently only one EST on the market, the EndoStim® LES Stimu-
lator developed by EndoStim Inc. [3]. The EndoStim® device has two gener-
ations. The first-generation device, EndoStim I®, has a larger battery lasting 
approximately 10 years. The second-generation device, EndoStim II®, is 25% 
thinner and has 40% less volume [9]. EndoStim II® has a battery lasting ap-
proximately 7 years. Correspondence with EndoStim Inc. indicated that the 
therapy delivered as well as the lead and electrodes used are identical in both 
devices. 
The main difference between EndoStim I® and EndoStim II® lies in their com-
patibility with Magnetic Resonance Imaging (MRI) scans. EndoStim II® an-
nounced the CE Mark approval for full body scans using 3.0 Tesla MRI ma-
chines in October 2015. Imaging of the head and extremities may also con-
tinue to be performed using both 1.5-Tesla and 3-Tesla systems [10]. In the 
United States, EndoStim II® seeks approval by the FDA and is currently al-
lowed for investigational use only [11]. 
Current standard procedure 
The current standard surgical treatment of GERD means wrapping the fun-
dus of the stomach around the esophagus to create a new valve at the level of 
the esophagogastric junction, a technique called fundoplication. Options in-
clude Nissen fundoplication and partial or Toupet fundoplication.  
 Nissen fundoplication is currently the gold-standard and the most com-
mon surgical treatment with around 2000 procedures carried out in 
Austria per annum. It was first performed in 1955 by an open tech-
nique, but it is now typically carried out laparoscopically. High-quality 
evidence suggests the superiority of laparoscopy to open surgery con-
cerning early outcomes (hospital stay, fewer complications) with no 
significant differences in late outcomes; although the reoperation rate 
is higher in the short-term [12, 13]. It is a complete or total wrap that 
encompasses 360° of the esophagus in a posterior fashion.  
 Partial fundoplication has two versions, but only one is recommended 
for the treatment of GERD, i.e Toupet fundoplication (posterior wrap), 
which covers roughly 270° of the posterior esophagus [13]. Partial fun-
doplication is associated with less post-operative dysphagia, fewer re-
operations, and its effectiveness is similar to total fundoplication in 
terms of controlling GERD symptoms up to five years after surgery. 
However, there are concerns about the long-term effectiveness of par-
tial fundoplication [12]. 
Laparoscopic fundoplication (LF) is technically difficult and it may be per-
formed differently by different surgeons, which has a high impact on patient 
outcomes. Although the most common is a loose (floppy) Nissen fundic wrap 
including a posterior hiatal hernia repair, the surgical technique has yet to be 
standardized to improve patient outcomes. 
The recovery time can be 4-6 weeks and patients may need to be on a pure 
liquid diet for one week after surgery before they can gradually start a soft 
food diet [14]. 
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Hiatal hernia and its repair 
The esophagus passes through an opening in the diaphragm (the oesophage-
al hiatus) before it joins the stomach. If the stomach slips through the dia-
phragm into the chest, a condition called hiatal hernia develops. Hiatal her-
nia might be a cause of GERD [15], therefore, depending on its size, it is of-
ten repaired (posterior crural repair) at the time of anti-reflux surgery at the 
surgeons’ discretion to ensure the success of the anti-reflux surgery. A sliding 
hernia of up to 3 cm can be effectively repaired by approximating the crura 
with interrupted stiches [16].  
Hiatal hernia repair can be done in both interventions. Fundoplication al-
lows for a concurrent hiatal hernia repair. LF is recommended for patients 
with hiatal hernia >2 cm or patients with their gastroesophageal junction in 
the chest [14].  
B0002 – What is the claimed benefit of the EST in relation  
to the alternative standard treatment option? 
The claimed major benefits of the EST compared to LF are its lesser inva-
siveness and reversibility [17]. The laparoscopic insertion of the device re-
quires little dissection and few steps, therefore, the operative time is shorter. 
The operation technique is less difficult, hence, its reproducibility is higher 
and the learning curve for the surgeon is also expected to be shorter [12, 18]. 
The EST procedure claims to be associated with fewer side-effects and a short-
er hospital length of stay [4]. 
B0003 – What is the phase of development and implementation  
of the EST and the alternative standard treatment option? 
The EST was first implanted in a clinical setting in Chile in a single-centre, 
prospective, open-label case series (NCT01578642) in 25 patients [8]. Corre-
spondence with the manufacturer suggests that device was first impanted in 
October 2010 and since then, 564 devices have been implanted. The EST is a 
novel technology that is in its emerging phase and hence, it is not part of the 
standard practice. Current clinical trials are investigating the use of the EST 
in other subgroups of GERD patients (after laparoscopic sleeve gastrectomy) 
that have been so far excluded from the use of the device [19]. Correspondence 
with EndoStim Inc. indicated that there is an ongoing study in the US and 
Europe that is a multicenter, randomized, double-blind, sham-controlled clin-
ical trial (NCT02749071), including results of the previously interrupted Eu-
ropean RCT (NCT02514616). This trial is supposed to serve as the basis for 
evaluation of efficacy of the EST for FDA approval. New versions of the de-
vice with substantial improvements are not expected in the near future. 
Fundoplication was first performed in 1955 and has become the standard sur-
gical anti-reflux treatment. It has several modifications, of which two (Nissen 
and Toupet) are most commonly used and accepted in the clinical practice. 
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Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers the EST and fundoplication  
and in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use the EST  
and the alternative standard treatment options? 
B0009 – What supplies are needed to use the EST  
and the alternative standard treatment option? 
Both the EST and LF are performed under general anaesthesia by a foregut 
surgeon. The guidelines suggest that LF is to be done in high-volume centres 
by experienced foregut surgeons. Surgeons with little experience should have 
expert supervision during their early experience with the procedure to min-
imize morbidity and improve patient outcomes [12].  
The premises, the operation team, and the supplies are similar; the only dif-
ference is the device itself.  
 
Regulatory & reimbursement status  
A0020 – For which indications has the electric stimulation therapy device 
(ESTD) received marketing authorisation or CE marking? 
The EndoStim® LES Stimulation System is intended for the treatment of pa-
tients with chronic GERD with symptom duration of 6 months or longer [9]. 
A0021 – What is the reimbursement status of the EST? 
To our knowledge, the EST is only reimbursed in Germany. The costs asso-
ciated with the EST operation include the price of the device (8.240 €), and 
the operation procedure (facilities, staff, anaesthesia, hospital stay). The in-
formation about the former was provided by the manufacturer.  
In comparison to fundoplication, the material costs (device) and the initial 
training of surgical staff to undertake the implantation procedure are addi-
tional to the costs of the LF operation procedure; although the EST proce-
dure might cost slightly less due to its shorter operation time. The Endo-
Stim® device is reimbursed in the German DRG-System up to the amount of 
12.508,49 €. In Austria, there are currently one centre where the EST is avail-
able. 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions and for what purposes  
is the EST used? 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
The EST is used in patients with GERD, which is defined according to the 
Montreal consensus as a condition that develops when the reflux of stomach 
contents causes troublesome symptoms and/or complications. Symptoms are 
considered troublesome if they adversely affect an individual’s well-being [1]. 
The EST is a second-line treatment for GERD patients in whom PPI medica-
tion failed to achieve complete symptom alleviation, symptoms recur despite 
initial successful medication, and for those who refuse to take life-long med-
ication or suffer from side-effects of PPI therapy. The main aim of the EST is 
alleviation of symptoms by strengthening the weak LES, the anatomical cause 
of GERD. The EST is not curative, but long-term (life-long) use is essential 
to maintain the treatment effect.  
From the surgical perspective, GERD is the failure of the anti-reflux barrier, 
which, when functioning improperly, allows abnormal reflux of gastric con-
tents into the esophagus. It is a mechanical disorder caused by a defective 
LES, a gastric emptying disorder, or failed esophageal peristalsis. The abnor-
malities result in a spectrum of disease ranging from symptoms only, such as 
heartburn, to esophageal tissue damage with or without subsequent compli-
cations, including malignancy or airway disease [1]. 
Reflux can be categorized based on symptoms or based on its nature.  
Symptom based approach differentiates between typical and atypical  
symptoms: 
 Typical symptoms: heartburn, regurgitation, epigastric pain. 
 Atypical symptoms: chronic cough, hoarseness, globus, dysphagia, 
chest pain, chronic aspiration, bronchitis, sinusitis.  
Based on its nature, GERD can be acid or non-acid.  
 Acid reflux with a pH<4.0 
 Non-acid reflux with a pH>4.0 
Non-acid reflux is poorly understood yet [14]. 
A generally accepted definition on the severity of GERD is lacking. Based on 
the frequency and severity of the experienced reflux symptoms, expressions 
used in the literature range from mild, through moderate, to severe GERD. 
However, there is no explicit definition clarifying the duration and measure-
ment of the symptoms.  
A0003 – What are the known risk factors  
for gastrooesophageal reflux disease (GERD)? 
There are anatomical and patient factors that can contribute to the develop-
ment of reflux. The anatomical factors are related to the LES, the diaphrag-
matic crura, and the phrenoesophageal ligament. The patient factors include 
diet and lifestyle, as well as obesity. Eating refluxogenic foods, overeating, 
GERD:  
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in die Speiseröhre 
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eating immediately before going to bed, increased fat consumption in the di-
et, and expanding proportion of obese individuals are significant risk factors 
for GERD. In obese patients, the intra-gastric pressure and the frequency of 
transient LES relaxations is chronically increased, which is thought to be the 
cause of GERD [14, 20]. 
A0004 – What is the natural course of GERD? 
The natural history of the disease has not been well clarified yet. Currently, 
two concepts exist: 
 The traditional concept sees the disease as a spectrum that starts with 
non-erosive reflux disease (NERD) and might progress to complicated 
GERD (erosive esophagitis, stricture, Barrett’s esophagus (BE)). This 
concept focuses on esophageal mucosal injury as the most significant 
clinical outcome in GERD. Patients with severe esophagitis are at high 
risk of developing a stricture and long-standing reflux symptoms are 
a major risk for developing BE. Patients with BE have an increased 
risk of esophageal adenocarcinoma with a 40 times greater incidence 
than in the general population [20]. 
 The new concept considers GERD as a categorical disease with three 
distinct entities: NERD, erosive esophagitis, and BE. According to this 
concept, these are different disorders and the movement among them 
is limited. This concept focuses on mechanisms leading to symptom 
generation rather than mucosal injury. Some studies suggest that GERD 
is a chronic disease that is not progressive. However, other studies con-
firm that progression of NERD to erosive esophagitis is possible in 
10% of GERD patients [20]. 
Both of these concepts assume that NERD might progress to GERD, it is 
debated though to what extent.  
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of GERD  
for the patients with the disease or health condition? 
Quality of life is impacted through the experience of GERD symptoms such as 
heartburn, extra-esophageal manifestations (pulmonary or ear, nose, throat), 
or non-cardiac chest pain [21].  
Patients often complain about sleep disturbance. Their diet is also affected 
as the foremost treatment suggested is life-style and diet modification. Pre-
sumably, they also need to take life-long medication that may have serious 
side effects, be badly tolerated, alter the absorption of minerals and vitamins, 
have metabolic effects on bone density, pharmacokinetics or pharmacody-
namics and related drug interactions and effects, or enhance the infection risk 
and hypersensitivity response with consequent organ damage [17]. 
A0006 – What are the consequences of GERD for the society? 
Due to its increasing incidence (approximately 5 per 1,000 person-years in 
the Western world [22]), GERD is leading to a growing utilisation of health 
resources (medical consultations, emergency room visits, hospitalization, and 
medication). Not only the doctor visits and diagnosis carry high financial ex-
penses, but also the medication and the operation costs need to be considered 
in the long run [23]. 
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The burden of disease on the individual affecting work productivity results 
in substantial societal burden and employer costs [17].  
 
Current clinical management of the disease or health condition 
A0024 – How is GERD currently diagnosed according  
to published guidelines and in practice? 
According to the American College of Gastroenterology (ACG) and the Ar-
beitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften 
(AWMF) Guidelines [24, 25], the recommendations for the diagnosis of GERD 
(along with the level of evidence and the level of strength of the recommenda-
tion) are the following: 
 A presumptive diagnosis of GERD can be established in the setting of 
typical symptoms of heartburn and regurgitation. Empirical medical 
therapy with PPIs is recommended in this setting (strong recommen-
dation, moderate level of evidence). 
 Patients with non-cardiac chest pain suspected due to GERD should 
have diagnostic evaluation before the institution of therapy (condition-
al recommendation, moderate level of evidence). A cardiac cause should 
be excluded in patients with chest pain before the commencement of 
a gastrointestinal evaluation (strong recommendation, low level of ev-
idence). 
 Upper endoscopy is recommended in the presence of alarm symptoms 
and for screening of patients at high risk for complications (strong re-
commendation, moderate level of evidence). 
 Ambulatory esophageal reflux monitoring is indicated before the con-
siderations of endoscopic or surgical therapy in patients with NERD, 
as part of the evaluation of those patients who are refractory to PPI 
therapy and in situations when the diagnosis of GERD is in question 
(strong recommendation, low level evidence). Ambulatory reflux mon-
itoring is the only test that can assess reflux symptom association (strong 
recommendation, low level of evidence). 
A0025 – How is GERD currently managed according  
to published guidelines and in practice? 
The management of GERD is aligned with the severity of symptoms. The 
ACG and AWMF Guidelines [24, 25] suggest a stepwise approach that starts 
with lifestyle modifications including: 
 Weight loss for GERD patients who are overweight or have had recent 
weight gain (conditional recommendation, moderate level of evidence). 
 Head of bed elevation and avoidance of meals 2-3 hours before bed-
time for patients with nocturnal GERD (conditional recommendation, 
low level of evidence). 
From mild to moderate severity symptoms, first a 
 H2-receptor antagonist (H2RA) therapy is recommended. This can be 
used as a maintenance option in patients without erosive disease if pa-
tients experience heartburn relief (conditional recommendation, mod-
erate level of evidence).  
 
ACG & AWMF: 
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If H2RA therapy is not sufficient and the patient has moderate to severe 
symptoms: 
 An 8-week course of PPIs is the therapy of choice for symptom relief 
and healing of erosive esophagitis. There are no major differences in 
efficacy between the different PPIs (strong recommendation, high lev-
el of evidence). 
 PPI therapy should be initiated at once a day dosing before the first 
meal of the day (strong recommendation, moderate level of evidence).  
 For patients with partial response to once daily PPI therapy, tailored 
therapy with adjustment of dose timing and/or twice daily dosing should 
be considered (strong recommendation, low level of evidence). Switch-
ing to a different PPI may provide additional symptom relief (condi-
tional recommendation, low level evidence). 
 Maintenance of PPI therapy should be administered for GERD pa-
tients who continue to have symptoms after PPI is discontinued and 
in patients with complications including erosive esophagitis and BE 
(strong recommendation, moderate level of evidence). For patients who 
require long-term PPI therapy, it should be administered in the low-
est effective dose, including on demand or intermittent therapy (con-
ditional recommendation, low level of evidence). 
 Non-responders to PPIs should be referred for evaluation  
(conditional recommendation, low level of evidence). 
Recommendations number 1-2 can only prevent approximately 20% of pa-
tients from a relapse. The relapse rate after discontinuation of the medication 
accounts for 90% [26].  
For patients with refractory GERD, there is no standardized management 
algorithm. The primary goal of the treatment is symptom reduction and even-
tual elimination [21]. 
The management of GERD is displayed in the following figure.  
 
Figure 4-1: Algorithmic approach to medical treatment of GERD [17] 
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PPI mit niedriger 
Dosierung indiziert 
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Management-
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PPI: proton pump inhibitor,  
H2RA: H2-receptor antagonist, GERD: gastroesophageal reflux disease 
Health Problem and Current Use 
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Life-style modifications and medical treatment are the first-line therapy op-
tions. Surgical management is the second-line treatment. Before considering 
surgery, objective documentation of the gastroesophageal reflux is mandatory. 
Surgical therapy should be considered in patients who: 
 have failed medical management (inadequate symptom control, severe 
regurgitation not controlled with acid suppression, or medication side 
effects); 
 opt for surgery despite successful medical management (due to quality 
of life considerations, lifelong need for medication intake, price of med-
ications, etc.); 
 have complications with GERD  
(e.g. BE, peptic stricture); 
 have extra-esophageal manifestations  
(asthma, hoarseness, cough, chest pain, aspiration). 
The coexistence of Barrett’s esophagus with gastroesophageal reflux symptoms 
is considered a clear indication for antireflux surgery. Surgical intervention 
for asymptomatic BE is, however, more controversial [1, 27]. 
It is important to note that there is no one best operation for all patients. 
Factors such as the degree of esophageal shortening, local expertise with 
laparoscopic techniques, prior operations and esophageal motility disorders, 
and the size of the hiatal hernia can influence the choice of operation [27]. 
Choice of surgical procedure is displayed in the following figure: 
 
TLESR: Transient lower esophageal sphincter relaxation; TIF: trans-oral incisionless fundoplication,  
LES: lower esophageal sphincter 
Figure 4-2: Decision tree in anti-reflux surgical therapy, adapted [14] 
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Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment is adult patients with moderate to 
severe GERD, who are considered for surgical treatment due to incomplete 
symptom control despite maximum medication treatment or severe compli-
cations associated with PPI therapy.  
A0023 – How many people belong to the target population?  
The prevalence of GERD is around 15% [1, 24] and the incidence is increas-
ing. It is the most common upper gastrointestinal disease in the Western coun-
tries with 10-20% of the population experiencing weekly symptoms [20]. 25-
42% of patients are refractory to a once-daily PPI, of which 25% would re-
spond to an increase in PPI dosing to twice daily. However, 42% of GERD 
patients are dissatisfied with their PPI treatment outcomes [21]. 
According to data from the Hauptverband, in 2014 in Austria, the Code LM030 
(open fundoplication/hiatusplasty) was reimbursed 98 times, the LM040 (lap-
aroscopic fundoplication/hiatusplasty) was refunded 1,723 times.  
A0011 – What is the expected annual utilisation of the EST? 
The expected annual utilisation of EST, according to the Hauptverband, based 
on the previous years’ experience, is 100 interventions per year in Austria.  
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 GERD HRQL 
Further outcomes considered were: 
 Heartburn 
 Regurgitation 
 Discontinuation with medication (PPIs) 
 Esophagitis 
GERD health-related quality of life score: 
Since, according to the traditional concept, GERD is a degenerative disease, 
the ultimate aim of the EST is to stop the process of degeneration by improv-
ing the function of the esophageal sphincter and thus improving the quality 
of life. Hence, GERD health-related quality of life (HRQL) score is consid-
ered a relevant primary outcome as the score represents a summation of pa-
tient-relevant items. It measures changes in typical GERD symptoms in re-
sponse to a surgical or medical treatment and so includes questions about 
heartburn, difficulty with swallowing, bloating, and medication intake. The 
best possible score is 0 (i.e., asymptomatic in each item) and the worst possi-
ble scores is 50 (incapacitated in each item). It also reflects on patient satisfac-
tion as it includes a question worded „How satisfied are you with your pre-
sent condition?” This item is a numerical score and it is not reflected in the 
total GERD-HRQL score (21). 
 
 
5.2 Included studies 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table 7-1. 
No study fulfilled the study inclusion criteria for assessing clinical effective-
ness of the EST. RCTs and non-randomised CTs were considered for inclu-
sion, but could not be identified through the systematic literature search (see 
Figure 2-1). 
The systematic literature search (see Figure 2-1) did not identify any com-
parative trials matching our inclusion criteria for efficacy. The two prospec-
tive case series [4, 5] and one prospective registry study [28] are described in 
the results on safety. 
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5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of the EST on mortality? 
No evidence was found to answer the research question. 
 
Morbidity 
D0005 – How does the EST affect heartburn, regurgitation,  
and extraesophageal symptoms? 
No evidence was found to answer the research question. 
D0006 – How does the EST affect the continuation with PPI therapy? 
No evidence was found to answer the research question. 
 
Function 
D0011 – What is the effect of the EST on dysphagia and bloating? 
No evidence was found to answer the research question. 
D0016 – How does the EST affect activities of daily living? 
No evidence was found to answer the research question. 
 
Health-related quality of life 
D0012 – What is the effect of the EST on disease-specific quality of life? 
No evidence was found to answer the research question. 
 
Patient satisfaction 
D0017 – Were patients satisfied with the EST? 
No evidence was found to answer the research question. 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Device erosion  
 Trocar perforation of the small bowel during laparoscopy  
Further outcomes considered were: 
 Post-operative bloating/belching  
 Post-operative dysphagia  
 Nausea/vomiting  
 Pain/discomfort 
 
 
6.2 Included Studies 
The study inclusion criteria for assessing safety differed from the ones for as-
sessing clinical effectiveness. In addition to RCTs and non-randomised CTs, 
prospective studies without a control group (interventional single arm studies, 
case series, and registry studies) were considered for the assessment of safety. 
The systematic literature search (see Figure 2-1) identified two prospective 
case series [4, 5] and one prospective registry study [28], which matched our 
inclusion criteria. Study characteristics and results of included studies are 
shown in Table A-1 and Table A-2, and in the evidence profile in Table 7-1. 
Study characteristics 
Overall, out of the total of 70 patients included in the studies, baseline char-
acteristics data were reported on 67 patients, of which 29 were women and 
38 were men. The registry study included 18 patients, but reported on 15 pa-
tients, of which 7 were women and 8 were men [28]. All three studies were 
sponsored by the manufacturer EndoStim Inc. Countries of recruitment were 
Colombia, India, Netherlands, Mexico, New Zealand, United Kingdom [4], 
and Chile [4, 5, 28]. Study recruitment times were October 2010 until Janu-
ary 2011 in the single center sace series [5], and April 2011 until July 2014 in 
the multi-centre case series [4], as stated by the manufacturer. Clinical fol-
low-up time ranged from 6 months to 3 years. Loss to follow-up ranged from 
6.8-19.2%. Model versions of the technology (generations of EndoStim®) were 
not reported in any of the studies. The multi-centre case series study included 
44 patients [4], the single-centre case series included 26 [5], and the registry 
18 patients [5, 28]. The registry study was a continuation of the single centre 
case series [5, 28]. 
Patient characteristics 
The mean age of patients varied between 49.6 [4]-56.1 [28]. The mean BMI 
ranged from 27.2-27.7 [4, 5]. There were differences in the presence of a hia-
tal hernia in the multi-centre [4] and the single centre study [5]: 39-88% of pa-
tients had no hiatal hernia, 8-22% of patients had hiatal hernia <2 cm, and 
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4-39% of patients with hiatal hernia >2 cm. The mean number of years that 
patients used PPIs was not stated in one study [4] and, in the remaining two 
studies, it was 5.6 [5] and 5.0 [28]. The mean number of years that patients 
experienced GERD symptoms prior to the study was not stated in one study 
[4] and, in the remaining two studies, it was 11 [5] and 12.2 [28].  
Patient inclusion and exclusion criteria of the single centre case series and 
the single centre registry were the same at baseline, however, the inclusion 
criteria for the patients that continued in the registry were not reported. 
The inclusion criteria shared by both case series were: previous reflux symp-
toms, prior PPI use, esophagitis grade ≤C, diagnosis based on 24-h pH mon-
itoring result, LES end-expiratory pressure of 5–15 mmHg, peristaltic contrac-
tions in ≥50% of swallows (respectively in 70% of swallows[5]) with contrac-
tion amplitude of ≥30 mmHg oesophageal manometry, and excessive lower 
esophageal acid exposure as pH <4.0 for ≥5% of the total time [4, 5]. 
In contrast, the two case series showed also several differences. The age range 
varied from 21-80 [4] to 21-65 years [5]. Improvement in GERD-HRQL score 
≥20 off PPIs and ≥10 on PPIs was an inclusion criterion in the single centre 
study [5], while in the multi-centre study, the increase of ≥5 on PPIs was suf-
ficient [4]. ASA Physical Status Classification ≤II was an inclusion criterion 
in the single centre study [5].  
Both case series reported patient exclusion criteria that mainly referred to 
history of esophageal surgery, multisystem disease, Barrett’s esophagus, any 
dysplasia, hiatal hernia ≥3 cm, BMI>35, history of diabetes mellitus, gastric 
malignancy, cardiac arrhythmia, cardiovascular disease, pregnancy, or im-
planted electro-medical devices [4, 5]. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is the EST in comparison to LF? 
In the absence of data from controlled studies, no comparisons can made be-
tween the EST and LF. Only device related complications can be considered 
for the analysis of safety because the effects directly attributable to the device 
can be analysed without a control group. 
Device related complications were reported in one study with 6 months fol-
low-up [4]. Lead erosion through esophagus occurred in 2.4% of patients and 
was followed by the device explantation. One procedure related complication, 
trocar perforation of the small bowel during laparoscopy, occurred also in 
2.4% of patients. No other device related complications were reported. 
C0002 – Are there harms related to dosage or frequency  
of applying the technology? 
Safe use of the EST is sensitive to the proper implantation and functioning 
of the implanted electronic device. Correct delivery of the electrical stimula-
tion, correct lead impedance (which was out of range in 4.8% of patients in 
one study [4]), and correct IPG implantation (where skin infections at pock-
et site occurred to 4% of patients [5]) are required. 
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C0004 – How does the frequency or severity of harms change  
over time or in different settings 
A number of short term post-operative harms occurred. The following adverse 
events occurred in one study [4] (in % of patients): constipation 2.4%, epigas-
tric pain 2.4%, hiccups 4.8%, inability to vomit 4.8%, and fever 2.4%. The fol-
lowing adverse events occurred in both case series [4, 5] (in % of patients): 
post-operative bloating/belching in 7.1% and 0%, post-operative dysphagia 
in 9.5% and 0%, nausea/vomiting in 7.1% and 12%, and pain/discomfort in 
45.2% and 20%. No new adverse events occurred in the registry study. 
The only known data to report on the safety profile differences between gen-
erations of the EST is the difference between compatibility of the device gen-
erations with MRI, where EndoStim® II is approved for full body scans us-
ing 3.0 Tesla MRI, while EndoStim® I can only be used for imaging of the 
head and extremities using 1.5-Tesla [10]. 
There is no evidence that harms increase or decrease in different organiza-
tional settings. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of the technology? 
Patient groups that are most likely to be harmed through the use of the tech-
nology are patients with other comorbidities. Cardiac patients are susceptible 
to harm as the EST may interact with the patient’s heart function or heart 
devices. Claimed to be unrelated to the EST, a SAE occurred in the multi-
centre study where a case of paroxysmal atrioventricular nodal re-entrant 
tachycardia (AVNRT) occurred several months after the start of the EST [4]. 
Furthermore, patients that are required to undergo magnet therapy are sus-
ceptible to harm as 4% of patients had the EST turned off by magnet therapy 
for arthritis [5]. Patients with psychological disorders are likely to be harmed 
as a case of psychotic disturbance/nervous breakdown occurred in 4% of pa-
tients in the single centre study [5]. Moreover, patients allergic to metals are 
susceptible to possible harm caused by the device as well as patients with 
eating disorders, as the case of weight loss/anorexia occurred in 11.9% of pa-
tients in the multi-centre study [4]. 
C0007 – Are the EST and LF associated with user-dependent harms? 
The learning curve for the implantation procedure of the EST is claimed to be 
short and the esophagogastric junction left unaltered, making the EST re-
versible [29]. When placing the electrodes, the surgeon needs to avoid perfo-
ration of the esophageal lumen [2]. Furthermore, correct set up of the elec-
trical stimulation by the gastroenterologist is crucial to minimize the risk of 
device malfunctioning. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of EST and LF? 
The existing registry study is missing some important information such as the 
device model type used, electrical set up of the device, reasons for deciding 
whether specific AEs and SAEs are related, possibly related, or unrelated to 
the intervention, and reporting on the outcomes of extraesophageal symptoms, 
hospital discharge, and improvement in esophagitis for all patients.  
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [1] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement a third researcher was involved to solve the difference. 
A more detailed list of criteria applied can be found in the recommendations 
of the GRADE Working Group [1].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1.  
Overall the strength of evidence for the effectiveness and safety of the EST is 
very low. No evidence was available for the comparison of the EST and LF.  
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Table 7-1: Evidence profile: efficacy and safety of the EST in GERD patients  
No of 
studies/patients Study Design 
Estimate  
of effect Study limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength of 
evidence 
Efficacy 
Due to the lack of a controlled group, no data on efficacy can be reported. 
Safety 
Adverse events (AEs) 
Post-operative bloating/belching 
3/67 [4, 5, 28] Prospective case series + prospective registry Not reported -11 -12 0 -13 Very low 
Post-operative dysphagia 
3/67 [4, 5, 28] Prospective case series + prospective registry Not reported -1 -1 0 -1 Very low 
Nausea/vomiting 
3/67 [4, 5, 28] Prospective case series + prospective registry Not reported -1 -1 0 -1 Very low 
Pain/discomfort 
3/67 [4, 5, 28] Prospective case series + prospective registry Not reported -1 -1 0 -1 Very low 
Serious adverse events (SAEs) 
Trocar perforation of the small bowel 
1/42 [4] Prospective case series Not reported -1 NA 0 -1 Very low 
Device erosion lead through esophagus 
1/42 [4] Prospective case series Not reported -1 NA 0 -1 Very low 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
 
                                                             
1 Unclear risk of bias due to unclear allocation concealment, no blinding, no control group 
2 Heterogeneous results, no p-value reported 
3 Small sample size 
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8 Discussion 
Because the Electric Stimulation Therapy is a new intervention that received 
the CE Mark in 2012 and currently seeks the FDA approval, there is scarce 
data on the clinical effectiveness and safety of the device. We could identify 
three prospective observational studies, two case series [4, 5] and one regis-
try study [28], including the total of 70 patients.  
Quality of evidence 
Overall, the quality of evidence was very low due to the observational study 
design, heterogeneity of data, no p-values on pre-post comparison reported, 
and small sample size (see Table 7-1). Also, the highly specific patient group 
is not representative of the range of GERD patients requiring anti-reflux sur-
gery due to the highly specific patient selection criteria [30]. The overall risk 
of bias was considered moderate because it was unclear if patients entered 
the study at similar point in the disease, if patients were recruited consecu-
tively, and conclusions concerning effectiveness were not supported by the re-
sults (see Appendix Table A-2). Internal validity of the trials conducted was 
undermined by the use of the concomitant therapy of PPIs in all trials. Oc-
casional or regular use of PPIs was reported to be 12% and 24% in the case 
series [4, 5], and 27% in the registry [28]. 
Effectiveness data from observational studies 
Large patient groups with non-acute diseases, such as the GERD patient 
group of this assessment, need the best evidence of controlled trials to prove 
effectiveness. The lack of RCTs and CTs restricted our analysis to single arm 
prospective studies as the best available evidence. Consequently, no conclu-
sions on effectiveness of the EST can be made. Nonetheless, the observational 
data from the prospective trials show a possible effect concerning crucial out-
comes. Both case series report improvement in GERD HRQL in on-PPI groups 
(improvement of 16.5-5 [4] and 9-0 [5]) and in off-PPI groups (improvement 
of 31-5 [4] and 23.5-0 [5]). The registry study reports slight deterioration by 
one point [29]. Improvement is also reported in the percentage of days with 
heartburn and regurgitation in both on-PPI and off-PPI groups and in medi-
an DeMeester pH score [7, 18, 29]. 
Improvement in discontinuation with medication (PPIs) was not reported in 
the multi-center study [18], but in in the remaining two studies, it was 76% 
[7] and 73% [29], respectively. The results were heterogeneous with reference 
to patient satisfaction, which improved from 7-54% in the multi-center study 
[18] and from 29-100% in the single center study [7]. Esophagitis improved 
slightly in the multi-center study [18], it was not reported in single centre [7], 
and insufficiently reported in the registry study [29]4.  
Safety data from observational studies 
With 3-year follow-up data at hand, longer-term data is needed to prove the 
safety of the EST. Relations between the EST and cardiac issues related either 
to cardiac devices, or to the EST itself remain to be answered.  
                                                             
4 Data reported on 66.6% of pts of which 50% showed improvement by 1 grade,  
25% had stable and 25% worsening esophagitis 
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In both the single center study and the registry study, the chair of the Data 
Monitoring Committee (DMC) was a consultant for EndoStim Inc. [5, 28] and 
because these two studies reported on less specific AEs and SAEs than the 
multi-center study [4], there might be a possibility of underreporting. The 
background of other committee members were not reported [4] and hence 
their independence cannot be evaluated. 
Mechanisms behind GERD 
The mechanisms behind GERD are unclear and only the correct determina-
tion of its pathophysiology will help in evaluating the efficacy of anti-reflux 
treatments [32]. Various surrogate outcomes such as esophageal manometry, 
24 pH monitoring, DeMeester score, or LES pressure attempt to quantify 
GERD. LES residual pressure, the main outcome that the EST claims to im-
prove, was either reported with a statistically insignificant improvement (p= 
0.8018) [4], or it was not reported in the remaining studies [5, 28]. Other 
mechanisms possibly having an influence on GERD may have effect on tran-
sient LES relaxations, LES compliance, or the acid pocket [5].  
As hiatal hernias makes acid reflux more likely [15], it is possible that re-
pairing of the hiatal hernia has an impact on the effectiveness of the inter-
vention and hence on GERD symptoms. One study reported on the variable 
of impact of repairing hiatal hernia ≥2 [4]. Patients with an unrepaired hiatal 
hernia ≥2 cm or a significant hiatal defect compared to patients with repaired 
hernia of the same size showed a trend for less improvement in GERD HRQL, 
percentage of heartburn days and nights, and percentage of regurgitation days 
and nights [4].  
Clinical trials 
Quality RCTs need to be conducted to prove the EST efficacy. DeMeester 
suggests that an RCT against PPIs is needed [31], whereas Attwood argues 
that a comparison between surgical options (EST vs LF) is required as only 
those patients who are dissatisfied with PPIs will be willing to undergo sur-
gery [32]. It is ambiguous what the appropriate comparator to the EST is. 
On the one hand, LF is the only established surgical alternative, yet on the 
other hand, the EST claims to fill the therapeutic gap between patients who 
are dissatisfied with the PPI treatment and those who are reluctant to under-
go LF. The target population of the EST seems to be less severe patients not 
indicated for fundoplication, which changes the cut-off point of a surgical 
intervention to the less diseased. In the light of this ambiguity, ethicality of 
an RCT between the EST and LF is put into question. Hence, under these cir-
cumstances, a sham RCT is needed to confirm efficacy of the EST.  
Since July 2015, there was an EndoStim Inc. funded sham RCT ongoing in 
Belgium and France that was terminated due to a suspension of financial sup-
port in November 2015 (NCT02514616). Correspondence with EndoStim Inc., 
however, suggests that the trial was discontinued because a new multi-center 
trial with a similar design and a larger sample was started. The sites origi-
nally participating in NCT02514616 will join the larger FDA approval study 
(NCT02749071). 
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Other technologies 
There are some other emerging technologies aiming to fill the above  
mentioned therapeutic gap. These can be categorized into 3 groups: 
1. radiofrequency ablation of the LES (Stretta System) 
2. trans-oral incisionless fundoplication (TIF),  
i.e. suturing of the gastroesophageal junction 
3. magnetic sphincter augmentation device (MSAD) [33, 34] 
The first two alternatives provide a non-surgical approach, while the MSAD 
is a laparoscopically implanted ring of magnetic beads made of titanium that 
is placed around the lower esophagus [33]. Like the EST, MSAD is a reversi-
ble procedure with an acceptable safety profile that is lacking robust data on 
its effectiveness. The TIF seems to be safe and effective with 79-80% response 
rates, but with disappointing 2-year follow-up results. It is equally recom-
mended only for patients with hiatal hernia <2 cm. The Stretta System is re-
commended by SAGES for non-complicated GERD and it is the only one 
that has undergone rigorous evaluation with randomized trials and positive 
effectiveness results [33, 34]. 
Untreated chronic reflux might lead to secondary diseases, such as erosive 
esophagitis, esophageal stricture, Barrett’s esophagus, or even esophageal can-
cer, therefore the effect of EST on these outcomes also needs to be analyzed. 
In the absence of clear severity scores supporting staging of well-defined in-
dications however, there is a possible issue with the EST that instead of a 
change in the patient’s dietary habits, particularly in the obese, the EST can 
facilitate unhealthy behaviour. In case the EST fulfils the mentioned thera-
peutic gap, it can be considered as the first line surgical treatment for preven-
tion of esophageal cancer and, on the long run, as an option bringing savings 
to the health care system when contrasted to the costly PPI therapy. Moreover, 
long-term PPI therapy can have serious side-effects, such as decreased calci-
um absorption, osteoporosis, community acquired pneumonia, Clostridium 
difficile infection, small intestinal bacterial overgrowth, vitamin B12 deficien-
cy, and drug interactions [35]. 
Major advantages of the EST known to date are that it is less invasive and 
reversible, its implantation is associated with a short learning curve for the 
surgeon, it presumably allows a faster return to normal diet, and it requires a 
short hospital stay compared to LF. Quality RCTs, in particular a sham RCT, 
with longer follow-up involving larger number of implanted patients should 
be conducted in order to prove efficacy of the EST. 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed  
and the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that the EST is at least equally 
effective and as safe as the comparator LF. There are no available compara-
tive data on the two procedures or placebo controlled data on the EST and 
hence, no conclusions are made about the device effectiveness. Concerning 
safety, only device related complications were reported based upon data from 
prospective case series. These suggest a relatively safe profile of the EST that, 
however, needs to be confirmed by a high quality RCT, which will potentially 
influence the effect estimate considerably.  
Currently, there is an ongoing sham-controlled RCT and hence the re-evalu-
ation is recommended in 2022, as December 2021 is its estimated study com-
pletion date.  
 
 
 
Evidenz unzureichend; 
derzeit nicht empfohlen 
1 laufendes RCT, 
Re-Evaluierung 2022 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: EST: Results from observational studies 
 Kappelle [4, 36] (2015) Rodriguez [5] (2015) Rodriguez [28] (2016) 
Country Chile, Colombia, India, Netherlands, Mexico, New Zealand,  
United Kingdom5 
Chile 
Sponsor EndoStim Inc. EndoStim Inc. 
Study design Multi-centre, prospective, international, open-label case series 
(NCT01574339) 
Single-centre, prospective. open-label case series 
(NCT01578642) 
Single-centre, prospective 
registry (NCT02441400) 
Intervention (I) Electric stimulation therapy (EndoStim® LES Stimulator) Electric stimulation therapy (EndoStim® LES Stimulator) 
Comparator (C) none none 
Number of pts (I vs. C) 446 267 188 
Inclusion criteria Pts 21-80yrs, reflux symptoms, GERD-HRQL score ≥20 off PPIs &, 
an increase of ≥5 on PPIs, prior PPI use for 12 mos, diagnosis based 
on 24-h pH monitoring result, LES end-expiratory 5–15 mmHg, 
peristaltic contractions in ≥50% of swallows with contraction 
amplitude of ≥30 mmHg oesophageal manometry, excessive lower 
esophageal acid exposure as pH <4.0 for ≥5% of the total time. 
Pts 21-65yrs, reflux symptoms ≥6mos, prior PPI use, 
GERD-HRQL score ≥20 off PPIs &, an increase of ≥10 
on PPIs, ASA Physical Status Classification ≤ II, distal 
esophageal acid exposure during 24-hour pH measure-
ment pH of ≤4 for>5% of total or>3% of supine, time 
off, anti-secretory therapy, LES end-expiratory 
≥5mmHg, esophageal body contraction amplitude of 
≥30 mmHg for ≥70% of swallows and ≥50% peristaltic 
contractions on manometry, esophagitis grade ≤C. 
NA 
Exclusion criteria History of esophageal or gastric surgery, gastroparesis, multi-
system disease, autoimmune or connective tissue disorder in past 
2 yrs, Barrett’s epithelium, any grade dysplasia, hiatal hernia >3 cm, 
esophagitis grade D on upper endoscopy within 6 mos, BMI>35, 
T1DM or uncontrolled T2DM defined as HbA1c ≥9.5 in the previous 
6ms, or T2DM for ≥10 years, suspected or confirmed esophageal or 
gastric cancer, any malignancy in last 2 yrs, esophageal or gastric 
varices or dysphagia or oesophageal peptic stricture, significant 
cardiac arrhythmia or cardiovascular disease, implanted electrical 
stimulator or chronic anticoagulant therapy, pregnant pts. 
Non-GERD esophageal motility disorders or 
gastroparesis, multi-system diseases, Barrett’s 
(>M2;>C1) esophagus, any grade of dysplasia, hiatal 
hernia ≥3 cm, BMI>35, uncontrolled type 2 or history 
of type 2 or 1 diabetes mellitus for >10 yrs, esophageal 
or gastric malignancy or varices, cardiac arrhythmia, 
ectopy, significant cardiovascular disease, implanted 
electro-medical device, pregnancy, esophageal or 
gastric surgery, anti-reflux surgery. 
NA 
                                                             
5 While the study refers to 8 countries and 10 sites, www.clinicaltrials.gov lists 7 countries and 9 sites. 
6 Baseline characteristics on 42pts 
7 25 received intervention 
8 Baseline characteristics on 15pts 
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 Kappelle [4, 36] (2015) Rodriguez [5] (2015) Rodriguez [28] (2016) 
Primary outcome measure    
Baseline patient 
characteristics (I vs. C) 
   
Mean age, yrs (SD) 49.6 (12.4) 52 (12) 56.1 (9.7) 
Sex, female vs. male  18 vs. 24 11 vs. 14 7 vs. 8 
Mean BMI, (SD) 
 Hiatal hernia  
 none/<2 cm/>2 cm, % 
 Mean yrs of PPI use (SD) 
 Mean yrs with GERD (SD) 
27.2 (2.4) 
39/22/39 
 
NA 
NA 
27.7 (3.2) 
88/8/4 
 
5.6 (3.4) 
11.0 (7.9) 
27.4 (3.2) 
93.3/0/6.7 
 
5.9 (3.3) 
12.2 (9.1) 
Follow-up time, yrs 0.5 2 3 
Loss to follow-up, % 6.89 19.210 16.611 
Outcomes 
Efficacy 
Improvement in median 
GERD HRQL score (pre-op./ 
last follow-up)12 (IQR) 
 on-PPI  
 off-PPI 
 
 
 
16.5 (9.0–22.8)/5.0 (3.0–9.0)13 
31.0 (26.2-36.8)/5.0 (3.0–9.0) 
 
 
 
9 (6–10)/0 (0–3)14/1 (0-2) 
23.5 (21–25.3)/0 (0–3)/1 (0-2) 
Median heartburn % of days 
(pre-op./last follow-up) (IQR) 
 days  
 nights 
 
 
86 (64–100)/17 (0–93)15 
64 (43–86)/0 (0–8) 
 
 
92/716/NA 
71/0/NA 
                                                             
  9 1 loss to follow-up, 1 Toupet fundoplication due to hiatal hernia >3 cm, 1 trocar perforation of the intestine during implant procedure 
10 1 loss to follow-up, 1 implant not attempted due to hiatal hernia >3 cm, 3 voluntary withdrawals 
11 of the 21pts at 2 yr follow-up, 3 did not join 5 year observational registry, 3 losses to follow-up 
12 The total GERD-HRQL score represents a summation of 10 items (questions about heartburn, difficulty swallowing, bloating, satisfaction and medication take).  
The best possible score is 0 (i.e., asymptomatic in each item), and the worst possible scores is 50 (incapacitated in each item) 
13 42 pts at baseline, 41 at last follow-up 
14 24 pts at baseline, 21 at last follow-up 
15 35 pts at baseline, 34 pts at last follow-up 
16 18 pts’ analysis 
  
A
p
p
en
d
ix 
LB
I-H
T
A
| 20
17 
4
7 
 Kappelle [4, 36] (2015) Rodriguez [5] (2015) Rodriguez [28] (2016) 
Median regurgitation % of 
days (pre-op./last follow-up) 
(IQR) 
 days  
 nights 
 
 
 
79 (54–100)/0 (0–21)17 
50 (15–79)/0 (0–7) 
 
 
 
66/018/NA 
31/0/NA 
Discontinuation with 
medication (PPIs), % at last 
follow-up 
NA 76/73 
Median DeMeester pH 
score19 (pre-op./last follow-
up) (IQR) 
35.1 (27.1–51.9)/17.5 (10.9–23.4)20 36.6 (29.6–50.2)/16.1 12.2–29.121/12.8 (7.2–18.8) 
Patient satisfaction while on 
PPIs at baseline, % (pre-op./ 
last follow-up) 
7/5422 29/100/NA 
Esophagitis, %  
(pre-op./last follow-up) 
 None  
 Grade A 
 Grade B  
 Grade C 
 
 
41/5123 
31/31 
23/18 
5/0 
 
 
NA/NA 
NA/NA 
NA/NA 
NA/NA 
 
 
0/NA24 
60/NA 
33.3/NA 
6.7/NA 
Safety 
Total number of AE 
Of which SAE 
AE related 
AE non-related 
110 (in 32pts) 
3 (2%) 
52 
56 
65 (in 19pts) 
2 (3%) 
NA 
 
  
                                                             
17 35 pts at baseline, 34 pts at last follow-up 
18 18 pts’ analysis 
19 Global measure of esophageal acid exposure that quantifies gastroesophageal reflux. A DeMeester score > 14.72 indicates reflux. 
20 42 pts at baseline, 40 at last follow-up 
21 24 pts at baseline, 18 at last follow-up 
22 42 pts at baseline, 39 at last follow-up 
23 out of 39 pts 
24 data on 12pts: 6pts showed improvement by 1 grade, 3pts has stable and 3pts worsening esophagitis 
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 Kappelle [4, 36] (2015) Rodriguez [5] (2015) Rodriguez [28] (2016) 
Device/procedure-related mild AEs noted during 
the study, % of pts  
Post-operative bloating/belching  
Constipation  
Post-operative dysphagia  
Epigastric pain  
Hiccups  
Nausea/vomiting  
Inability to vomit  
Weight loss/anorexia  
Fever  
Pain/discomfort  
Impedance out of range  
Mesh repair hernia cicatricialis  
Skin infection at pocket site 
Psychotic disturbance/nervous breakdown 
Shoulder pain and a hypersensitive episode 
 
 
7.1 
2.4 
9.5 
2.4 
4.8 
7.1 
4.8 
11.9 
2.4 
45.2 
4.8 
2.4 
NA 
NA 
NA 
 
 
0 
NA 
0 
NA 
NA 
12 
NA 
NA 
NA 
20 
NA 
NA 
4 
4 
8 
 
 
0 
NA 
0 
NA 
NA 
0 
NA 
NA 
NA 
0 
NA 
NA 
0 
0 
0 
Device/procedure-related SAEs 
Intraoperative complications in % of pts 
 Trocar perforation of the small bowel during 
laparoscopy 
Postoperative complications in % of pts 
 Device related complications (Lead erosion 
through esophagus, explantation) 
 Reoperation rate 
 Hospital readmission 
 
 
2.4 
 
 
2.4 
 
NA 
NA 
 
 
NA 
 
 
NA 
 
NA 
NA 
 
 
NA 
 
 
NA 
 
NA 
NA 
MSAD – Magnetic Sphincter Augmentation Device, LP – Laparoscopic, LF – Laparoscopic Fundoplication, PPI – Proton Pump Inhibitor; Pts – patients;  
GERD HRQL – Gastroesophageal Reflux Disease Health-Related Quality of Life, BMI – Body Mass Index, yrs – year; mos – months; min – minutes; pre-op. – pre-operative;  
AEs – adverse events; SAEs – serious adverse events; NA – data not available 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[37] and in the Guidelines of EUnetHTA [38].  
Table A-2: Risk of bias – study level 
 Prospective case series Prospective registry 
Study reference/ID Kappelle [4, 36], 2015 Rodriguez [5], 2015  Rodriguez [28], 2016 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section? Yes Yes Yes 
2. Are the characteristics of the participants included in the study described? Yes Yes Yes 
3. Were the cases collected in more than one centre? Yes No No 
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate? Yes Yes Yes 
5. Were participants recruited consecutively? Unclear25 Unclear26 Unclear27 
6. Did participants enter the study at similar point in the disease? Unclear Unclear28 Unclear 
7. Was the intervention clearly described in the study? Yes Yes Yes 
8. Were additional interventions (co-interventions) clearly reported in the study? Yes Yes Yes 
9. Are the outcome measures clearly defined in the introduction or methods section? Yes Yes Yes 
10. Were relevant outcomes appropriately measured with objective and/or subjective methods? Yes Yes Yes 
11. Were outcomes measured before and after intervention? Yes Yes Yes 
12. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes Yes 
13. Was the length of follow-up reported? Yes Yes Yes 
14. Was the loss to follow-up reported? Yes Yes Yes 
15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? Yes Patrially reported Yes 
16. Are adverse events reported? Yes Yes Yes 
17. Are the conclusions of the study supported by results? Partially reported Partially reported Partially reported 
18. Are both competing interest and source of support for the study reported? Yes Yes Yes 
 Moderate Moderate Moderate 
                                                             
25 “Unclear”: 110pts screened and 66 specified screen failures 
26 “Unclear”: 75pts screened and 49 unspecified screen failures 
27 “Unclear”: 21pts at 24mos follow-up, 18 recruited for 5 yr registry (3/21 elected not to join the 5 year observational registry) 
28 “Unclear”: only mean duration of PPI use and mean duration of GERD symptoms is reported. 
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Applicability table 
Table A-3: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Study population represents a narrow spectrum of GERD patients as predifined by the manufacturer and hence for the most part, the target population does 
not differ from the enrolled population. The inclusion criteria predominantly do not reflect severe refractory GERD with hiatal hernias >3 cm, motility disorders, 
Barrett’s easophagus or grade D esophagitis, but only mild to moderate GERD with incomplete symptom control by PPIs. 
Intervention Electric stimulation therapy device (EST) inserted through laparoscopic surgery. 
Product name: EndoStim® LES Stimulator 
Comparators Standard surgical treatment of GERD and Nissen fundoplication and partial, or Toupet fundoplication. However, there is a slight ambiguity as EST attempts to 
place itself into the „treatment gap” for which there is no comparator. It aims at patients who have persistant GERD, incomplete symptom control by PPIs, but 
whose condition is not severe enough to undergo any type of non-reversible fundoplication. 
Outcomes Effectiveness outcomes reported in the registry study are GERD HRQL, heartburn, regurgitation, discontinuation with PPI medication, DeMeester score,  
patient satisfaction, and esophagitis. Follow-up time was 0.5 to 3 yrs.The outcomes measured present the most important benefits. 
Safety outcomes that are most frequently reported in the three studies considered are post-operative bloating/belching, post-operative dysphagia, 
nausea/vomiting, pain/discomfort, device and procedure related side effects. Follow-up time ranged from 0.5 to 3 yrs and hence short-term safety profile of the 
EST on GERD may be assessed even though its comparative safety to LF cannot. The outcomes measured do present the most important health threats 
associated with the EST. 
Setting All of the studies included were either single-centre or multi-centre studies, with clinical centres based in Europe, South and Central America, Asia, New 
Zealand, and the United States. Clinical settings were not described in all of the studies, but it is likely that all patients received-standard care at university 
hospitals or transplant centres. 
Thus, it can be assumed that the results reflect a wide spectrum of clinical routines with regard to patient selection and treatment modalities and,therefore, the 
results are transferable to the Austrian setting. The surgeon’s technical expertise likely determines the risk of local side effects. If introduced as a new treatment 
method in European hospitals, the treatment with EST will certainly be accompanied by a learning curve. 
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List of ongoing trials 
Table A-4: List of ongoing trials of the EST 
Identifier/ 
Trial name 
Patient  
population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT02441400 
EndoStim Patient Registry 
(RESTORE) 
Patients with 
GERD 
EndoStim® LES 
Stimulator 
Single arm, no 
comaprison group 
Assessment of safety by incidence and severity 
of adverse events through 60-month (5 years) 
follow-up. 
May 2019 EndoStim Inc. 
LESS GERD Registry Patients with 
GERD 
EndoStim® LES 
Stimulator 
Single arm, no 
comaprison group 
NA NA EndoStim Inc. 
NCT02749071 29 
An Investigation of the EndoStim® 
Lower Esophageal Sphincter (LES) 
Stimulation System for the 
Treatment of Reflux 
Patients with 
GERD 
EndoStim® LES 
Stimulator 
Sham Rate of (occurence) device and/or procedure-
related serious adverse events in 12mos 
Percentage of subjects achieving pH success 
(pH<4 for mo more than 5.3% of time or at 
least 50% improvement in pH compared to 
baseline) 
June 2017 EndoStim Inc. 
NCT02514616 
Electrical Stimulation Therapy (EST) 
of the Lower Esophageal Sphincter 
(GERD) (EST-SHAM-EUR) 
Patients with 
GERD 
EndoStim® LES 
Stimulator 
Sham Efficacy of EST on GERD symptoms (mean 
improvement in the GERD- health-related 
quality of life (HRQL) scores from baseline in 
control and treatment groups) at 14 weeks 
follow-up 
November 2015 EndoStim Inc. 
NCT02210975 
An Investigation of Electrical 
Stimulation on Gastroesophageal 
Reflux Disease (GERD) in Patients 
After Sleeve Gastrectomy 
Patients with 
GERD after Sleeve 
Gastrectomy 
EndoStim® LES 
Stimulator 
No comparitor The incidence and severity of any 
complications that are associated with the 
investigational stimulation device throughout 
the follow-up period at 12 month follow-up 
Disease specific quality of life at 6 and  
12 month follow-up 
January 2016 EndoStim Inc. 
 
 
                                                             
29 Terminated to become part of a larger trial NCT02749071 
Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD) 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Electrostimulation for GERD 
Search Date: 02/01/2017 18:03:53.310 
Description: (MEL2017 MS/KR) 
ID Search 
#1 MeSH descriptor: [Gastroesophageal Reflux] explode all trees 
#2 „gastro*esophageal reflux“ (Word variations have been searched) 
#3 „gastro-esophageal reflux“ (Word variations have been searched) 
#4 GER:ti,ab,kw (Word variations have been searched) 
#5 GERD:ti,ab,kw (Word variations have been searched) 
#6 GORD:ti,ab,kw (Word variations have been searched) 
#7 #1 or #2 or #3 or #4 or #5 or #6  
#8 MeSH descriptor: [Electric Stimulation Therapy] explode all trees 
#9 Electric* near Stimul*:ti,ab,kw (Word variations have been searched) 
#10 MeSH descriptor: [Electric Stimulation] explode all trees 
#11 electrostimul*:ti,ab,kw (Word variations have been searched) 
#12 electro-stimul*:ti,ab,kw (Word variations have been searched) 
#13 EST:ti,ab,kw (Word variations have been searched) 
#14 EndoStim:ti,ab,kw (Word variations have been searched) 
#15 LES near Stimul*:ti,ab,kw (Word variations have been searched) 
#16 #8 or #9 or #10 or #11 or #12 or #13 or #14  
#17 #7 and #16 
Total: 23 Hits 
 
Search strategy for CRD 
Search Name: Electrotherapy for GERD (MEL2017 MH/KR) 
Search Date: 02/01/2017 
ID Search 
#1 MeSH DESCRIPTOR Gastroesophageal Reflux EXPLODE ALL TREES 
#2 (gastro*esophageal reflux) 
#3 (gastro-esophageal reflux) 
#4 (gastro-oesophageal reflux) 
#5 (GER) 
#6 (GERD) 
#7 (GORD) 
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 
#9 MeSH DESCRIPTOR Electric Stimulation Therapy EXPLODE ALL TREES 
#10 (Electric* NEAR Stimul*) 
#11 MeSH DESCRIPTOR Electric Stimulation EXPLODE ALL TREES 
#12 (electrostimul*) 
#13 (electro-stimul*) 
#14 (EST) 
#15 (EndoStim) 
#16 (LES NEAR Stimul*) 
#17 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 
#18 #8 AND #17 
Total: 2 Hits 
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Search strategy for Embase 
Search Name: Electrostimulation for GERD 
Search Date: 02/01/2017 
ID Search 
#23 ‘gastroesophageal reflux’/exp OR ‘gastroesophageal reflux’:ab,ti OR ‘gastrooesophageal reflux’:ab,ti OR 
‘gastro-esophageal reflux’:ab,ti OR ‘gastro-oesophageal reflux’:ab,ti OR ger:ab,ti OR gerd:ab,ti OR  
gord:ab,ti AND (‘electrotherapy’/mj OR (electric* NEAR/5 stimul*):ti,ab OR ‘electrostimulation’/exp OR 
lectrostimul*:ti,ab OR ‘electro stimul*’:ti,ab OR est:ti,ab OR endostim:dn OR endostim*:ti,ab OR les:dn OR 
(les NEAR/1 stimul*):ti,ab) 
Total: 264 Hits 
 
Search strategy for Medline 
Search Name: Electrostimulation for GERD 
Search Date: 02/01/2017 
ID Search 
#1 1 exp Gastroesophageal Reflux/(26275) 
#2 2 gastro?esophageal reflux.mp. (31464) 
#3 3 gastro-?esophageal reflux.mp. (1502) 
#4 4 GER.mp. (3394) 
#5 5 GERD.mp. (7461) 
#6 6 GORD.mp. (788) 
#7 7 1 or 2 or 3 or 4 or 5 or 6 (34515) 
#8 8 exp Electric Stimulation Therapy/(74443) 
#9 9 (Electric* adj5 Stimul*).mp. (168133) 
#10 10 exp Electric Stimulation/(132669) 
#11 11 (therap* or treatment* or program*).mp. (6907194) 
#12 12 10 and 11 (16907) 
#13 13 electrostimul*.mp. (3382) 
#14 14 electro-stimul*.mp. (309) 
#15 15 EST.ti,ab. (11102) 
#16 16 EndoStim.mp. (11) 
#17 17 LES Stimul*.mp. (76) 
#18 18 8 or 9 or 12 or 13 or 14 or 15 or 16 or 17 (230916) 
#19 19 7 and 18 (150) 
#20 20 remove duplicates from 19 (128) 
Total: 128 Hits 
 
Search strategy for PubMed 
Search Name: MELs 2017: Electric Stimulation Therapy for patients with GERD 
Search Date: 03/02/2017 
ID Search 
#1 ((„Gastroesophageal Reflux“[Mesh] OR „gastroesophageal reflux“ OR „gastrooesophageal reflux“ OR  
„gastro-esophageal reflux“ OR „gastro-oesophageal reflux“ OR GER OR GERD OR GORD)) AND (Electric 
Stimulation Therapy OR (Electric Stimulation AND (therap* OR treatment* OR program* OR procedure* OR 
intervention* OR technolog*)) OR electrostimul* OR electro-stimul* OR EST[tiab] OR EndoStim OR  
„LES Stimulator“) 
Total: 99 Hits 
 
  
 
 
